| [1] |
Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61(2): 69-90.
|
| [2] |
赫捷，陈万青．2012中国肿瘤登记年报．军事医学科学出版社，2012.
|
| [3] |
陈琼，刘志才，程兰平．2003~2007年中国结直肠癌发病与死亡分析．中国肿瘤，2012，21(3): 179-182．
|
| [4] |
Fisher B, Wolmark N, Rockette H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer:results from NSABP protocol R-01. J Natl Cancer Inst, 1988, 80(1): 21-29.
|
| [5] |
Wolmark N, Wieand HS, Hyams DM, et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst, 2000, 92(5):388-396.
|
| [6] |
Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet, 2009, 373(9666): 811-820.
|
| [7] |
Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med, 2004, 351(17): 1731-1740.
|
| [8] |
L. Pahlman, B. Glimelius, B. Cedermark, et al. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med, 1997, 336(14): 980-987.
|
| [9] |
Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg, 2006, 93(10): 1215-1223.
|
| [10] |
Siegel R, Burock S,Wernecke KD, et al. Preoperative short course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomized study of the Berlin Cancer Society. BMC Cancer, 2009, 9: 50.
|
| [11] |
Hofheinz RD, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol, 2012, 13(6): 579-588.
|
| [12] |
Aschele C,Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol, 2011, 29(20): 2773-2780.
|
| [13] |
Gérard JP, Azria D,Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol, 2010, 28(10): 1638-1644.
|
| [14] |
Rödel C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol, 2012, 13(7): 679-687.
|
| [15] |
O'Connell MJ, Colangelo LH, Beart RW, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol, 2014, 32(18): 1927-1934.
|
| [16] |
Wong SJ, Moughan J, Meropol NJ, et al. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neo-adjuvantradiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys, 2015, 91(1): 116-123.
|
| [17] |
Klautke G, Küchenmeister U, Foitzik T, et al. Intensified irinotecan-based neoadjuvant chemoradiotherapy in rectal cancer: four consecutive designed studies to minimize acute toxicity and to optimize efficacy measured by pathologic complete response. Radiother Oncol, 2007, 85(3): 379-384.
|
| [18] |
Hofheinz RD, von Gerstenberg-Helldorf B, Wenz F, et al. Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. J Clin Oncol, 2005, 23(7): 1350-1357.
|
| [19] |
Velenik V, Ocvirk J, Oblak I, et al. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer. Eur J Surg Oncol, 2010, 36(3): 244-250.
|
| [20] |
Sun PL, Li B, Ye QF, et al. Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study. Int J Colorectal Dis. 2012, 27(10): 1325-1332.
|
| [21] |
L. S. Blaszkowsky, D. P. Ryan, J. Szymonifka, et al. Phase I/II study of neoadjuvant bevacizumab,erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer. Ann Oncol, 2014, 25(1): 121-126.
|
| [22] |
Fernández-Martos C, Pericay C, Aparicio J, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol, 2010, 28(5): 859-865.
|
| [23] |
Fernandez-Martos C, Garcia-Albeniz X, Pericay C, et al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial.Ann Oncol, 2015, 26(8): 1722-1728.
|
| [24] |
Cercek A, Goodman KA, Hajj C, et al. Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. J Natl Compr Canc Netw, 2014, 12(4): 513-519.
|
| [25] |
Pettersson D, Holm T,Iversen H, et al. Preoperative short-course radiotherapy with delayed surgery in primary rectal cancer. Br J Surg, 2012, 99(4): 577-583.
|
| [26] |
Faria S, Kopek N, Hijal T, et al. Phase II trial of short-course radiotherapy followed by delayed surgery for locoregionally advanced rectal cancer. Colorectal Dis, 2014, 16(2): 66-70.
|
| [27] |
Myerson RJ, Tan B, Hunt S, et al. Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer. Int J Radiat Oncol Biol Phys, 2014, 88(4): 829-836.
|
| [28] |
Garcia-Aguilar J, Smith DD,Avila K,et al. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg, 2011, 254(1): 97-102.
|
| [29] |
Garcia-Aguilar J,Chow OS, Smith DD, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol, 2015, 16(8): 957-966.
|
| [30] |
Zhu J, Gu W, Lian P, et al. A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma. Radiat Oncol, 2013, 8: 130.
|
| [31] |
Zhu J, Liu F, Gu W, et al. Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectaladenocarcinoma: results of a phase II study. Radiat Oncol, 2014, 9: 70.
|
| [32] |
Appelt AL, Pløen J, Harling H, et al. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol, 2015, 16(8): 919-927.
|
| [33] |
Chessin DB, Enker W, Cohen AM, et al. Complications after preoperative combined modality therapy and radical resection of locally advanced rectal cancer: a 14-year experience from a specialty service. J Am Coll Surg, 2005, 200(6): 876-882.
|
| [34] |
Hendren SK, O'Connor BI, Liu M, et al. Prevalence of male and female sexual dysfunction is high following surgery for rectal cancer. Ann Surg, 2005, 242(2): 212-223.
|
| [35] |
Sajid MS, Farag S, Leung P, et al. Systematic review and meta-analysis of published trials comparing the effectiveness of transanal endoscopic microsurgery and radical resection in the management of early rectal cancer. Colorectal Dis, 2014, 16(1): 2-14.
|
| [36] |
Ung L, Chua TC, Engel AF. A systematic review of local excision combined with chemoradiotherapy for early rectal cancer. Colorectal Dis, 2014, 16(7): 502-515.
|
| [37] |
Garcia-Aguilar J, Renfro LA, Chow OS, et al. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncol, 2015, 16(15): 1537-1546.
|
| [38] |
Lezoche E, Baldarelli M, Lezoche G, et al. Randomized clinical trial of endoluminal locoregional resection versus laparoscopic total mesorectal excision for T2 rectal cancer after neoadjuvant therapy. Br J Surg, 2012, 99(9): 1211-1218.
|
| [39] |
Hong YS, Nam BH, Kim KP, et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol, 2014, 15(11): 1245-1253.
|
| [40] |
Yanhong Deng, Pan Chi, Ping Lan, et al. A multi-center randomized controlled trial of mFOLFOX6 with or without radiation in neoadjuvant treatment of local advanced rectal cancer (FOWARC study): Preliminary results. J Clin Oncol, 2015, 33: (suppl; abstr 3500).
|
| [41] |
Valentini V, van Stiphout RG, Lammering G, et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol, 2011, 29(23): 3163-3172.
|
| [42] |
Shen L,van Soest J, Wang J, et al. Validation of a rectal cancer outcome prediction model with a cohort of Chinese patients. Oncotarget, 2015, 6(35): 38327-38335.
|